Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention


  Free Subscription


3 Antimicrob Agents Chemother
1 Clin Infect Dis
1 Emerg Infect Dis
1 Eur Respir J
1 J Bacteriol
3 N Engl J Med
3 PLoS One
2 Proc Natl Acad Sci U S A

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles


  1. CHAISSON LH, Semitala FC, Mwebe S, Katende J, et al
    Transaminitis prevalence among HIV-infected adults eligible for tuberculosis preventive therapy.
    AIDS. 2022 Jun 23. pii: 00002030-990000000-00051.
    PubMed         Abstract available

    Antimicrob Agents Chemother

  2. ABOLHASSANI-CHIMEH R, Akkerman OW, Saktiawati AMI, Punt NC, et al
    Population Pharmacokinetic Modelling and Limited Sampling Strategies for Therapeutic Drug Monitoring of Pyrazinamide in Patients with Tuberculosis.
    Antimicrob Agents Chemother. 2022 Jun 21:e0000322. doi: 10.1128/aac.00003.
    PubMed         Abstract available

  3. KAWUMA AN, Wasmann RE, Dooley KE, Boffito M, et al
    Population Pharmacokinetic Model and Alternative Dosing Regimens for Dolutegravir Coadministered with Rifampicin.
    Antimicrob Agents Chemother. 2022 May 23:e0021522. doi: 10.1128/aac.00215.
    PubMed         Abstract available

  4. WALTER K, Kokesch-Himmelreich J, Treu A, Waldow F, et al
    Interleukin-13-Overexpressing Mice Represent an Advanced Preclinical Model for Detecting the Distribution of Antimycobacterial Drugs within Centrally Necrotizing Granulomas.
    Antimicrob Agents Chemother. 2022;66:e0158821.
    PubMed         Abstract available

    Clin Infect Dis

  5. HEYSELL SK, Mpagama SG, Ogarkov OB, Conaway M, et al
    Pharmacokinetic-pharmacodynamic determinants of clinical outcomes for rifampin-resistant tuberculosis: a multi-site prospective cohort study.
    Clin Infect Dis. 2022 Jun 22. pii: 6613372. doi: 10.1093.
    PubMed         Abstract available

    Emerg Infect Dis

  6. SHEA J, Smith C, Halse TA, Kohlerschmidt D, et al
    Novel Mycobacterium tuberculosis Complex Genotype Related to M. caprae.
    Emerg Infect Dis. 2022;28:1431-1436.
    PubMed         Abstract available

    Eur Respir J

  7. CHUNG C, Shin JE, Jeon D, Kang H, et al
    Treatment outcomes of multidrug-resistant tuberculosis with chronic kidney/liver disease.
    Eur Respir J. 2022 Jun 16. pii: 13993003.00930-2022.

    J Bacteriol

  8. GOAR H, Paul P, Khan H, Sarkar D, et al
    Molecular Connectivity between Extracytoplasmic Sigma Factors and PhoP Accounts for Coupled Mycobacterial Stress Response.
    J Bacteriol. 2022;204:e0011022.
    PubMed         Abstract available

    N Engl J Med

  9. TURKOVA A, Palmer M, Gibb DM
    Shorter Treatment for Tuberculosis in Children. Reply.
    N Engl J Med. 2022;386:2439-2440.

  10. MISHRA G, Mulani J
    Shorter Treatment for Tuberculosis in Children.
    N Engl J Med. 2022;386:2439.

  11. CHEN S
    Shorter Treatment for Tuberculosis in Children.
    N Engl J Med. 2022;386:2438-2439.

    PLoS One

  12. BILCHUT AH, Mekonnen AG, Assen TA
    Knowledge of symptoms and delays in diagnosis of extrapulmonary tuberculosis patients in North Shewa zone, Ethiopia.
    PLoS One. 2022;17:e0270002.
    PubMed         Abstract available

  13. YOUN HM, Shin MK, Jeong D, Kim HJ, et al
    Risk factors associated with tuberculosis recurrence in South Korea determined using a nationwide cohort study.
    PLoS One. 2022;17:e0268290.
    PubMed         Abstract available

  14. XI Y, Zhang W, Qiao RJ, Tang J, et al
    Risk factors for multidrug-resistant tuberculosis: A worldwide systematic review and meta-analysis.
    PLoS One. 2022;17:e0270003.
    PubMed         Abstract available

    Proc Natl Acad Sci U S A

  15. Correction for Chiner-Oms et al., Gene evolutionary trajectories in Mycobacterium tuberculosis reveal temporal signs of selection.
    Proc Natl Acad Sci U S A. 2022;119:e2208725119.

    Conserving rhinoceros in the face of disease.
    Proc Natl Acad Sci U S A. 2022;119:e2206438119.

Thank you for your interest in scientific medicine.

AMEDEO Tuberculosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.